A Phase 4 interventional study of Atorvastatin suspension and Lipitor in Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-10.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 72nd largest by enrollment of the 75 interventional ones that give a count, is one of 13 that started in 2008, is one of 28 in phase 4, and was the 34th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 13 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Hypercholesterolemia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 19 studies in Hypercholesterolemia by Viatris Inc., this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2008, is one of 8 in phase 4, and was the 12th registered.
Viatris Inc.’s Hypercholesterolemia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
Among Viatris Inc.’s 19 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development.
Estimation of Relative Bioavailability
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Extemporaneous preparation suspension Atorvastatin prototype formulation
Drug: Atorvastatin suspension
Commercial atorvastatin tablet (Lipitor®)
Drug: Lipitor
A single dose of 80 mg Atorvastatin suspension
A single dose of 80 mg Lipitor tablet
Also known as: Atorvastatin
Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48)
Geometric means of AUC48 = area under the plasma concentration-time profile from time zero (0) to 48 hours postdose of atorvastatin (test versus \[vs\] reference); measured in nanograms times hour per milliliter (ng.hr/mL).
Time frame: 5 days
Area Under the Curve From Predose (Time Zero) to Extrapolated Infinite Time (AUC Infinity)
Geometric means of AUC infinity (AUCinf) = area under the plasma concentration-time curve from time zero (0) extrapolated to infinite time; measured in ng.hr/mL of atorvastatin (test vs reference).
Time frame: 5 days
Maximum Observed Plasma Concentration (Cmax)
Geometric mean of Cmax = maximum observed plasma concentration of atorvastatin (test vs reference); measured in nanograms per milliliter (ng/mL).
Time frame: 5 days
Area Under the Curve From Predose (Time Zero) to Last Quantifiable Concentration (AUClast)
Geometric mean of AUClast = area under the plasma concentration-time curve from time zero (0) to the last measurable concentration of atorvastatin (test vs reference); measured as ng.hr/mL
Time frame: 5 days
Terminal Phase Rate Constant (Kel)
Geometric mean of Kel= termination phase rate constant for atorvastatin (test vs reference); measured as 1 per hour (1/hr).
Time frame: 5 days
Time to Reach Maximum Plasma Concentration (Tmax)
Median of Tmax = time to maximum plasma concentration (Cmax) (test vs reference); measured in hours (hr).
Time frame: 5 days
Plasma Elimination Half-life (t1/2)
Mean of t1/2 = terminal elimination half-life of atorvastatin (test vs reference); measured in hours.
Time frame: 5 days
One center in the U.S.
| Milestone | Test Drug First (Atorvastatin EP Suspension) | Reference Drug First (Atorvastatin Tablet) |
|---|---|---|
| Started | 6 | 6 |
| Completed | 5 | 6 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Test Drug First (Atorvastatin EP Suspension) | Reference Drug First (Atorvastatin Tablet) |
|---|---|---|
| Started | 5 | 6 |
| Completed | 5 | 6 |
| Not completed | 0 | 0 |
Geometric means of AUC48 = area under the plasma concentration-time profile from time zero (0) to 48 hours postdose of atorvastatin (test versus \[vs\] reference); measured in nanograms times hour per milliliter (ng.hr/mL).
| ng.h/mL | Test | Reference |
|---|---|---|
| Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48) | 135.05 (52.5 to 233.00) | 140.79 (64.10 to 243.00) |
Geometric means of AUC infinity (AUCinf) = area under the plasma concentration-time curve from time zero (0) extrapolated to infinite time; measured in ng.hr/mL of atorvastatin (test vs reference).
| ng.hr/mL | Test | Reference |
|---|---|---|
| Area Under the Curve From Predose (Time Zero) to Extrapolated Infinite Time (AUC Infinity) | 135.88 (51.20 to 234.00) | 142.86 (65.00 to 247.00) |
Geometric mean of AUClast = area under the plasma concentration-time curve from time zero (0) to the last measurable concentration of atorvastatin (test vs reference); measured as ng.hr/mL
| ng.hr/mL | Test | Reference |
|---|---|---|
| Area Under the Curve From Predose (Time Zero) to Last Quantifiable Concentration (AUClast) | 130.21 (45.50 to 231.00) | 137.49 (56.00 to 243.00) |
Geometric mean of Cmax = maximum observed plasma concentration of atorvastatin (test vs reference); measured in nanograms per milliliter (ng/mL).
| ng/mL | Test | Reference |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 38.74 (20.30 to 86.80) | 33.24 (16.60 to 52.20) |
Geometric mean of Kel= termination phase rate constant for atorvastatin (test vs reference); measured as 1 per hour (1/hr).
| 1/hr | Test | Reference |
|---|---|---|
| Terminal Phase Rate Constant (Kel) | 0.12 (0.09 to 0.26) | 0.10 (0.06 to 0.15) |
Median of Tmax = time to maximum plasma concentration (Cmax) (test vs reference); measured in hours (hr).
| hr | Test | Reference |
|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) | 0.52 (0.50 to 2.00) | 0.50 (0.50 to 3.00) |
Mean of t1/2 = terminal elimination half-life of atorvastatin (test vs reference); measured in hours.
| hr | Test | Reference |
|---|---|---|
| Plasma Elimination Half-life (t1/2) | 5.95 ± 1.40 | 7.21 ± 2.23 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test | — | 0/12 (0%) | 1/12 (8.3%) |
| Reference | — | 0/11 (0%) | 1/11 (9.1%) |
| Event | Test | Reference |
|---|---|---|
| headacheNervous system disorders | 1/12 | 1/11 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 34.8 ± 7.7 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 0 |
| Male | 12 |
The record gives a start of Feb 2008, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →